Epigeneres Biotech operationalise the HrC test – an early warning system that picks up cancer signals

Subject :Science and Technology

Section: Biotechnology

Context:

An early warning system for cancer, that’s the promise of HrC or the Himanshu Roy Cancer test – a first-of-its-kind prognostic test for cancer.

Details of HrC test:

It was developed by the city-based Epigeneres Biotechnology along with Singapore-based Tzar Labs, supported by some marquee investors.
The test is named after mumbai’s top cop Himanshu roy.
the test involves a single blood test that claims to detect the absence, imminence or presence of cancer.
The test detects all cancers from a blood test; it catches imminent cancer “very early” and it’s “very accurate” of the “stage zero” test that detects a potential cancer risk 18 months earlier, the company claims.
The test has been launched in India, priced at sub-₹10,000. With a capacity of 15 samples daily the aim is to get to 50-100 samples a day.
Besides cancer survivors, the test would help people with a family history of cancer or with a risk profile.
The company is now discussing taking this technology to the United Kingdom and the US.